CN110545797A - 预防性地防止、减慢阿尔茨海默病的进展或治疗阿尔茨海默病的方法 - Google Patents

预防性地防止、减慢阿尔茨海默病的进展或治疗阿尔茨海默病的方法 Download PDF

Info

Publication number
CN110545797A
CN110545797A CN201880020544.0A CN201880020544A CN110545797A CN 110545797 A CN110545797 A CN 110545797A CN 201880020544 A CN201880020544 A CN 201880020544A CN 110545797 A CN110545797 A CN 110545797A
Authority
CN
China
Prior art keywords
patient
high density
density lipoprotein
blood
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880020544.0A
Other languages
English (en)
Chinese (zh)
Inventor
小霍利斯·布莱恩·布鲁尔
迈克尔·M·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HDL Therapeutics Inc
Original Assignee
HDL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/876,808 external-priority patent/US20190021674A1/en
Application filed by HDL Therapeutics Inc filed Critical HDL Therapeutics Inc
Priority claimed from PCT/US2018/020502 external-priority patent/WO2018160868A1/en
Publication of CN110545797A publication Critical patent/CN110545797A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Disabilities (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
CN201880020544.0A 2017-03-01 2018-03-01 预防性地防止、减慢阿尔茨海默病的进展或治疗阿尔茨海默病的方法 Pending CN110545797A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762465262P 2017-03-01 2017-03-01
US62/465,262 2017-03-01
US201762516100P 2017-06-06 2017-06-06
US62/516,100 2017-06-06
US201762537581P 2017-07-27 2017-07-27
US62/537,581 2017-07-27
US15/876,808 2018-01-22
US15/876,808 US20190021674A1 (en) 2017-01-23 2018-01-22 Methods for Treating Cholesterol-Related Diseases
PCT/US2018/020502 WO2018160868A1 (en) 2017-03-01 2018-03-01 Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CN110545797A true CN110545797A (zh) 2019-12-06

Family

ID=67682480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880020544.0A Pending CN110545797A (zh) 2017-03-01 2018-03-01 预防性地防止、减慢阿尔茨海默病的进展或治疗阿尔茨海默病的方法

Country Status (5)

Country Link
EP (1) EP3589272A4 (enExample)
JP (2) JP2020509036A (enExample)
CN (1) CN110545797A (enExample)
AU (1) AU2018226803A1 (enExample)
CA (1) CA3053491A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019264938A1 (en) * 2018-05-11 2020-12-03 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke
CN116662835A (zh) * 2022-02-18 2023-08-29 医疗研究开发有限公司 分层方法以及分层装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US9580492B2 (en) * 2007-02-23 2017-02-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize anthrax toxins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1641421T (pt) * 2003-07-03 2019-03-27 Hdl Therapeutics Inc Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
PT2089417E (pt) * 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
EP2152309B1 (en) * 2007-05-14 2013-07-10 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US9580492B2 (en) * 2007-02-23 2017-02-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize anthrax toxins

Also Published As

Publication number Publication date
CA3053491A1 (en) 2018-09-07
EP3589272A1 (en) 2020-01-08
AU2018226803A1 (en) 2019-08-29
JP2023071648A (ja) 2023-05-23
EP3589272A4 (en) 2020-11-25
JP2020509036A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
US20220202857A1 (en) Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
US20230355180A1 (en) Methods for Treating Cholesterol-Related Diseases
US20080214438A1 (en) Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US8637460B2 (en) Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20190381070A1 (en) Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke
JP2023071648A (ja) アルツハイマー病を予防的に防止し、その進行を遅らせ、または処置するための方法
JP2021523182A (ja) 脳アミロイド血管症、アルツハイマー病及び／又は急性脳卒中を予防する、進行を遅延させる、又は治療するための方法
WO2018160868A1 (en) Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease
US20190070257A1 (en) Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Alzheimer's Disease
US20230140014A1 (en) Methods and Systems for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer’s Disease, and/or Acute Stroke
WO2023064794A1 (en) Methods and systems for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke
US20200171086A1 (en) Methods for Treating Lipid-Related Diseases Including Xanthomas, Carotid Artery Stenoses, and Cerebral Atherosclerosis
CN113365643A (zh) 用于治疗包括黄色瘤、颈动脉狭窄和脑动脉粥样硬化的脂质相关疾病的方法
HK1087945B (en) Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
HK1087945A (en) Methods and apparatus for creating particle derivatives of hdl with reduced lipid content

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191206

RJ01 Rejection of invention patent application after publication